You appear to be target-fixated on the SP (like most folks here on this board)...
...and missing the forest. The IP is what has the value.
BP will take one look at the BOD of IPIX and not want to have anything to do with them developing literally anything most likely.
I've already heard this from multiple contacts within both financial industries as well as competitive BioTechs.
Where the value lies, is in the IP. How long the patent life extends, and what sort of market exclusivity exists. Ease of use along with scope of applications is critical as well (for determining market-size for application).
An outright sale or license is where things should likely head, given what's on the table.
I can't imagine anyone wanting these guys to further develop anything they're sitting on, nor do they have the resources to do so.
SP has literally nothing to do with any of this. It's not a bargaining-tool.
If IPIX burns to the ground and we lose it all, the IP still exists and has monetary value.
Think about that.
News 
Market Data 
Discover 
AI
